<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783250</url>
  </required_header>
  <id_info>
    <org_study_id>350</org_study_id>
    <nct_id>NCT00783250</nct_id>
  </id_info>
  <brief_title>Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>Effect of Bronchodilators on Respiratory Mechanics in COPD Patients With Poor Reversibility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effects on respiratory mechanics of one &quot;classical&quot;
      short-term bronchodilator (i.e., salbutamol) versus placebo, and to verify the hypothesis
      that the addition of another bronchodilator (i.e., anticholinergic) may induce a further
      improvement on the work of breathing of stable COPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies with long-acting b2-agonists in COPD patients who poorly respond to routine airways
      obstruction reversibility tests with forced expiratory manoeuvres, such as forced expiratory
      volume in one second (FEV1), are scarce. Such studies, however, seem to show favourable
      effects on clinical parameters.

      This may explain the subjective improvements and changes in quality of life with long-acting
      b2-agonists in patients with COPD. The lack of effect on forced expiration tests may be due
      to early airway collapse and subsequent airflow decline causing underestimation of the
      existing bronchodilatory effects located more peripherally in the respiratory tract, where
      the major site of resistance is located in obstructive lung disease.

      We therefore design a study aimed to assess the short term effects of one short-acting
      beta2-agonist vs placebo, and the effects of an additional and sequential administration of a
      different bronchodilator, like tiotropium bromide (anticholinergic agent) on the work of
      breathing, and its components (i.e., lung resistances and compliance) of COPD patients with
      poor reversibility assessed using the classical Pulmonary Function Tests.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Problems with data collection
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recordings of respiratory mechanics</measure>
    <time_frame>90 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea score</measure>
    <time_frame>90 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Salbutamol+Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salbutamol will be given at the dose of 400 micrograms and Tiotropium at the dose of 18 micrograms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo + Tiotropium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo using MDI + administration of Tiotropium after 20 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol + Tiotropium</intervention_name>
    <description>Salbutamol 400 micrograms + Tiotropium 18 micrograms</description>
    <arm_group_label>Salbutamol+Tiotropium</arm_group_label>
    <other_name>Ventolin</other_name>
    <other_name>Spiriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Tiotropium</intervention_name>
    <description>Placebo via MDI + Tiotropium 18 micrograms</description>
    <arm_group_label>placebo + Tiotropium</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD patient with a Tiffenau ratio &lt;55% and &gt;25% predicted

          -  Poor reversibility to an acute bronchodilator test (i.e. FEV1 changes&lt;10% from
             baseline)

        Exclusion Criteria:

          -  Lack of informed consent

          -  Cancer

          -  Concomitant lung and airways diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Respiratory Unit Fondazione S.Maugeri</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>dr. Stefano Nava</investigator_full_name>
    <investigator_title>Chief ICU</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Respiratory Mechanics</keyword>
  <keyword>Bronchodilators</keyword>
  <keyword>COPD patients with poor reversibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

